A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-design Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Latest Information Update: 23 May 2024
At a glance
- Drugs Deudextromethorphan (Primary)
- Indications Agitation
- Focus Registrational; Therapeutic Use
- Sponsors Avanir Pharmaceuticals; Otsuka Pharmaceutical Development & Commercialization
- 23 May 2024 According to Otsuka Pharmaceutical media release, after a detailed analysis of results from the completed trial, Otsuka and OPDC have decided to terminate the development of this drug candidate.
- 03 Apr 2024 Status changed from active, no longer recruiting to completed.
- 12 Feb 2024 Primary endpoint (Change from Baseline to Week 12 in the composite Cohen-Mansfield) has not been met.